Compass Therapeutics, Inc. (CMPX)
(Delayed Data from NSDQ)
$2.91 USD
-0.02 (-0.68%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.92 +0.01 (0.34%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Compass Therapeutics, Inc.'s return on equity, or ROE, is -42.48% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that CMPX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CMPX 2.91 -0.02(-0.68%)
Will CMPX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMPX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPX
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
CMPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
Other News for CMPX
Compass Therapeutics (CMPX) Receives Outperform Rating from Raymond James | CMPX Stock News
Compass Therapeutics resumed with an Outperform at Raymond James
Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer
Compass Therapeutics (CMPX) Receives a Buy from Piper Sandler
Compass Therapeutics management to meet virtually with Piper Sandler